Fulcrum Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines to improve the lives of patients with genetically defined rare diseases. Historically, the company leveraged its proprietary gene regulatory network discovery platform to systematically identify and validate drug targets capable of modulating gene expression. Its lead clinical programs were losmapimod, developed for facioscapulohumeral muscular dystrophy (FSHD), and pociredir (an oral small-molecule inhibitor of Embryonic Ectoderm Development, or EED), developed for sickle cell disease (SCD). However, following major clinical and regulatory setbacks, the company has pivoted to exploring strategic alternatives.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiation of a comprehensive review of strategic alternatives to maximize stockholder value, following the termination of the pociredir program. The company has engaged Leerink Partners LLC as its financial advisor to assist in evaluating options such as a merger, acquisition, business combination, or asset sale.
Expected impact: Potential transaction to merge, sell, or combine the business to leverage its substantial cash reserves of $333.3 million.
Implementation of a deep restructuring plan to significantly reduce operating expenses and preserve capital. The plan includes reducing the workforce by approximately 85%, from 57 full-time employees to 9 full-time employees.
Expected impact: Significant reduction in ongoing cash burn to extend the runway of the company's remaining cash and investments.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Fulcrum previously held a worldwide exclusive license to CAMP4's Diamond-Blackfan anemia program. However, on April 23, 2026, Fulcrum provided written notice to terminate this license agreement to focus resources on core benign hematology efforts (prior to the subsequent discontinuation of pociredir).
Terms: Fulcrum previously paid an undisclosed upfront payment and achieved/paid a $0.6 million preclinical milestone in 2025.
A collaboration for the development and commercialization of losmapimod in facioscapulohumeral muscular dystrophy (FSHD). The agreement was terminated following the discontinuation of the losmapimod program.
Terms: Fulcrum originally received an upfront payment of $80.0 million in 2024, but the collaboration was terminated in 2025, resulting in $0 collaboration revenue for the full year 2025.